A detailed history of Vanguard Group Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,547,075 shares of GLUE stock, worth $22.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,547,075
Previous 1,635,829 55.71%
Holding current value
$22.5 Million
Previous $11.5 Million 17.4%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.38 - $7.86 $3.08 Million - $7.16 Million
911,246 Added 55.71%
2,547,075 $9.53 Million
Q1 2024

May 10, 2024

BUY
$4.26 - $8.46 $201,975 - $401,105
47,412 Added 2.98%
1,635,829 $11.5 Million
Q4 2023

Feb 14, 2024

SELL
$2.5 - $5.93 $99,900 - $236,962
-39,960 Reduced 2.45%
1,588,417 $8.97 Million
Q3 2023

Nov 14, 2023

BUY
$4.78 - $7.22 $342,195 - $516,872
71,589 Added 4.6%
1,628,377 $7.8 Million
Q2 2023

Aug 14, 2023

BUY
$4.53 - $8.4 $495,373 - $918,573
109,354 Added 7.56%
1,556,788 $10.7 Million
Q1 2023

May 15, 2023

BUY
$5.95 - $8.21 $123,284 - $170,111
20,720 Added 1.45%
1,447,434 $11.3 Million
Q4 2022

Feb 10, 2023

BUY
$6.71 - $9.72 $127,805 - $185,136
19,047 Added 1.35%
1,426,714 $10.9 Million
Q3 2022

Nov 14, 2022

SELL
$7.17 - $12.16 $6.13 Million - $10.4 Million
-855,239 Reduced 37.79%
1,407,667 $11.5 Million
Q2 2022

Aug 12, 2022

SELL
$6.15 - $14.99 $4.55 Million - $11.1 Million
-739,866 Reduced 24.64%
2,262,906 $21.9 Million
Q1 2022

May 13, 2022

BUY
$10.36 - $20.41 $19.9 Million - $39.2 Million
1,922,156 Added 177.88%
3,002,772 $42.1 Million
Q4 2021

Feb 14, 2022

BUY
$16.28 - $27.15 $986,486 - $1.65 Million
60,595 Added 5.94%
1,080,616 $22.1 Million
Q3 2021

Nov 12, 2021

BUY
$18.59 - $42.21 $17.1 Million - $38.8 Million
920,021 Added 920.02%
1,020,021 $22.7 Million
Q2 2021

Aug 13, 2021

BUY
$18.86 - $22.7 $1.89 Million - $2.27 Million
100,000 New
100,000 $2.27 Million

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $413M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.